How Dr. Millie Samaniego bridged the gap between study use and routine care by extending protocolized use

In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her

How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance, in-line with ASTS recommended use

Detect. Monitor. Optimize: Signatera’s Impact on Breast Cancer Management

Learn more about the latest Signatera™ data in high-risk breast cancer: Newly published data from the I-SPY 2 trial reinforcing the utility of ctDNA monitoring

How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the recent CMS update

Hear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about his dd-cfDNA “surveillance journey” and protocol development.

Post-ASCO Summary: ctDNA as a patient selection and early efficacy marker in drug development

Our expert speakers will discuss the latest data from ASCO 2023 and other recent publications and congresses. This will be followed by a panel discussion on the future directions and implications for